The Details: Invo BioScience said the combined company will continue to operate its fertility business as well as expand its focus to the development of clinical-stage assets in oncology and ...

Invo reports $1.38 million in quarterly sales, representing a 396.15% increase over sales of $278,140 from the same period last year. The company says it remains on-track with its goal of reaching ...

Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued ...

Valued at less than $54 million in market capitalization, and with total annual sales barely passing the $1 million mark, Sarasota, Florida-based INVO Bioscience (INVO) is hardly a household name -- ...

SARASOTA, Fla., Nov. 7, 2019 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Beverly-based Invo Bioscience Inc. is looking to address a ...

Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative ...

BEVERLY, Mass.--(BUSINESS WIRE)--INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced that INVO Bioscience ...

BEVERLY, Mass., Jan. 20, 2012 /PRNewswire/ -- INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that ...